Can a smart dosing tool prevent heart transplant rejection in children?

NCT ID NCT04380311

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This study tests a personalized dosing tool for tacrolimus, an immunosuppressant drug given to children after a heart transplant to prevent organ rejection. The tool uses a computer model that considers each child's age, kidney function, and other medications to calculate the best dose. The goal is to see if this approach helps children reach the target drug level faster and more consistently than standard dosing, which could improve long-term transplant outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Tacrolimus dosing support tool (a computer model that personalizes tacrolimus doses based on patient factors)
What this could lead to
If successful, this could lead to a more precise way to dose tacrolimus in children after heart transplant, potentially reducing rejection and improving long-term transplant survival.
What could go wrong
This is a small study (17 participants) and compares against historical data, so results may not be definitive. The tool's accuracy depends on the model's assumptions and may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART TRANSPLANT FAILURE AND REJECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Rejection, Psychology transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Primary Children's Hospital

    Salt Lake City, Utah, 84112, United States

  • University of Utah

    Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.